The Creatinine Mask

How the Deception Works

The most common kidney function test—estimated glomerular filtration rate (eGFR)—is calculated from serum creatinine using equations that include age, sex, and race as proxy variables for muscle mass. The assumption: a 70-year-old woman produces less creatinine than a 30-year-old man because she has less muscle. Adjust for that, and creatinine becomes a reliable indicator of how well the kidneys filter.

The problem: the equations assume typical muscle mass for demographic categories. They don't measure actual muscle mass. And many patients don't have typical muscle mass.

Consider a patient receiving chemotherapy. The treatment causes muscle wasting (cachexia)—a common side effect of many cancer treatments. As muscle mass drops, creatinine production drops proportionally. Less creatinine enters the blood. The serum creatinine level falls. The eGFR calculation—seeing lower creatinine—reports improved kidney function.

But the kidneys haven't improved. They may actually be declining, damaged by the same chemotherapy causing the muscle loss. The "improvement" is an artifact of the measurement method.

The Clinical Consequences

Many medications are dosed based on kidney function, particularly drugs that the kidneys excrete. Antibiotics, antivirals, diabetes medications, blood thinners, and chemotherapy agents all require dose adjustment for reduced kidney function. If the kidney function estimate is falsely elevated, the dose will be too high.

For a patient with true GFR of 30 mL/min (moderate kidney disease) whose creatinine mask shows eGFR of 60 mL/min (mild kidney disease), the medication dose could be double what's appropriate. This increases drug levels in the blood, amplifies side effects, and risks toxicity.

The populations most vulnerable to creatinine mask are also those most likely to receive renally-dosed medications: the elderly (natural muscle loss), cancer patients (treatment-related cachexia), patients with chronic illness (disease-related wasting), and those who've been immobilized (hospitalization, injury). The mask affects precisely the patients for whom accurate dosing matters most.

A section about one person’s own test results was here. It is not on the public site: nothing here comes from any individual’s medical record.

The Alternative: Cystatin C

Cystatin C is a protein produced by all nucleated cells at a relatively constant rate—it doesn't depend on muscle mass. When kidneys filter properly, cystatin C is cleared efficiently and blood levels stay low. When filtration declines, cystatin C accumulates.

eGFR calculated from cystatin C doesn't have the muscle-mass blind spot. For patients with abnormal muscle mass—whether high (athletes, bodybuilders) or low (elderly, ill, cachectic)—cystatin C provides more accurate kidney function assessment.

The ideal approach uses both markers. Equations that combine creatinine and cystatin C outperform either alone. When the two estimates diverge significantly—creatinine-based eGFR much higher than cystatin-based eGFR—that divergence itself is diagnostic of muscle wasting.

Why This Matters for VSI

The creatinine mask illustrates a broader principle: standard metrics assume standard physiology. When patients deviate from assumptions—which complex patients often do—the metrics mislead rather than inform.

This is why the VSI framework emphasizes personal baselines and trends over population reference ranges. A creatinine of 0.8 mg/dL means something different for someone whose historical baseline was 1.2 mg/dL than for someone whose baseline was 0.8 mg/dL. The absolute number fits within "normal range" either way, but the trajectory tells different stories.

The seven-minute constraint makes this kind of nuanced interpretation rare. Physicians see a creatinine in normal range and move on. There's no time to check whether muscle mass might be confounding the result, to request cystatin C for confirmation, or to compare against historical values.

AI-human partnership can help here. Computational systems can track longitudinal data, flag discordant results, and prompt deeper investigation when patterns suggest the creatinine mask might be operating. The AI doesn't replace physician judgment—it extends the time available for the kind of careful analysis that prevents patients from falling through measurement gaps.